Eli Lilly's Diabetes And Obesity Drugs Blow Past Expectations; Shares PopInvestors Business Daily • 08/05/26
Eli Lilly raises annual revenue forecast as obesity, diabetes drug demand stay strongReuters • 08/05/26
Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surgeCNBC • 08/05/26
Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progressPRNewsWire • 08/05/26
Novo Nordisk Stock Stumbles On A Key Miss As Its Battle With Eli Lilly Heats UpInvestors Business Daily • 08/04/26
Eli Lilly Is Up 7% in 2026 and Has Major Catalysts on the Way. Is the Rally Just Getting Started?The Motley Fool • 08/04/26
Read Between These Lines As Eli Lilly, Hot IPO And More Face Key TestInvestors Business Daily • 08/03/26
Will Mounjaro & Zepbound Drive Lilly's Q2 Results: Buy, Sell or Hold?Zacks Investment Research • 08/03/26
Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancerPRNewsWire • 08/03/26